Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Onset Seizuresin Patients with Epilepsy
Links shared publicly online about this topic.
- 520total visits
Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Onset Seizuresin Patients with Epilepsy
Perampanel is a new drug in development for the treatment of partial onset seizures in patients with epilepsy. Perampanel information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Seizure, Epilepsy, Drug, Clinical Trial, Eisai, News
Most Recently Shared on February 8, 2011 at 11:06 pm By:
Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Thera... http://bit.ly/f9NnXc #drug
Advertisement
